Randomized,double-blind,double-dummy,controlled clinical trial of pioglitazone/metformin in the treatment of type 2 diabetes

HU Hong-lin,WANG Chang-jiang,ZHANG Mu-xun,YAN Sheng-li,LIU Jun-jiang,ZHU Lv-yun,HE Yong,GAO Ya

DOI: https://doi.org/10.3969/j.issn.1001-6821.2009.06.001

2009-01-01

Abstract:Objective To evaluate the efficacy and safety of pioglitazone /metformin hydrochloride in the treatment of type 2 diabetes mellitus patients.Methods A randomized,double-blind,metformin and pioglitazone hydrochloride-controlled,and multicenter clinical trial was conducted.A total of 240 patients with type 2 diabetes mellitus were enrolled in this study,in which 120 patients received pioglitazone/metformin,and 120 patients received metformin and pioglitazone.Result Comparing to the baseline,the fasting blood glucose(FBG),2 h postprandial blood glucose(P2hBG) and HbA1c levels in tow groups were significantly reduced after 16-week treatment(P<0.01).In pioglitazone/metformin group,the mean reductions of FBG,P2hBG and HbA1c levels were(1.92±1.77) mmol·L-1,(2.49±3.13) mmol·L-1,(1.27±1.45)% respectively.In metformin and pioglitazone group,the mean reductions of FBG,P2hBG and HbA1c levels were(2.24±2.11) mmol·L-1,(2.89±3.71) mmol·L-1,(1.49±1.52)% respectively.The differences in reductions of FBG,P2hBG and HbA1c level between the groups were not statistically significant.The incidence of adverse drug reaction in two groups was similar(10% vs 12%).Conclusion This result provides an efficacy and safety of pioglitazone /metformin in the treatment of type 2 diabetes mellitus.